Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles (Tables)

v3.21.4
Acquisition of Patents and Intangibles (Tables)
6 Months Ended
Nov. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of net purchase price and allocation to the acquired assets

​

​

​

​

​

​

​

​

(in thousands)

    

November 30, 2021

    

May 31, 2021

Leronlimab (PRO 140) patent

​

$

3,500

​

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

​

 

2,926

​

​

2,926

Website development costs

​

 

20

​

 

20

Gross carrying value

​

​

6,446

​

​

6,446

Accumulated amortization, net of impairment

​

 

(5,293)

​

 

(4,793)

Total amortizable intangible assets, net

​

$

1,153

​

$

1,653

Schedule of estimated future amortization expense

​

​

​

​

​

Fiscal Year (in thousands)

    

Amount

2022 (6 months remaining)

​

$

221

2023

​

​

217

2024

​

​

85

2025

​

​

85

Thereafter

​

​

545

Total

​

$

1,153